ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®
May 17 2022 - 5:34AM
Business Wire
The ChromaDex External Research Program
(CERPTM) was honored in the “Nutrition Research Project” category
for pioneering research behind Niagen®
ChromaDex Corp. (NASDAQ:CDXC) announced today that
NutraIngredients, a leading news source for the nutrition industry,
recently honored the ChromaDex External Research Program (CERPTM)
with a 2022 European NutraIngredients Award in the “Nutrition
Research Project” category for developing the science behind
ChromaDex’s proprietary and patented Niagen® nicotinamide riboside
(NR) ingredient. Niagen is an efficient precursor for the essential
cellular coenzyme nicotinamide adenine dinucleotide (NAD+), which
stimulates cellular energy production and supports cellular repair.
Decreased NAD+ levels have been associated with age-related decline
in overall health.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220517005235/en/
ChromaDex Wins 2022 NutraIngredients
Award for Developing the Science Behind Niagen® (Graphic: Business
Wire)
Honoring the best and brightest in ingredients, products,
companies, people, and initiatives in the nutrition and dietary
supplement industry, the NutraIngredients Awards spotlight
innovation, long-term market success, and cutting-edge research.
The Nutrition Research Project category assessed companies that
showcased sound science to back up claims and inform business
decisions, and awarded the best game-changing nutrition research
projects that push boundaries of nutritional science.
“As a pioneer of NAD+ and NR science via Niagen, we are honored
to receive this award and garner recognition for the innovative
research CERP is leading throughout the world,” said Dr. Andrew
Shao, ChromaDex Senior Vice President of Global Regulatory and
Scientific Affairs. “Through CERP, we are furthering research on
the benefits of Niagen and NAD+ by collaborating with the global
research community and the NutraIngredients Award for the best
Nutrition Research Project reinforces our dedication to this.”
CERP is an essential component of ChromaDex’s Research and
Development Program, where Niagen and other materials (bulk,
clinical, and matching placebo) are provided, in kind, for
outstanding research proposals. Additionally, a group of ChromaDex
interdisciplinary scientists supports the technical and
intellectual property needs of investigators, presents research at
conferences, and is helping to uncover the benefits of Niagen and
NAD+ within the healthy aging research community on a global
scale.
The judges for the 2022 EU NutraIngredients Awards said that
“life improvement for older populations is a global challenge and
demonstrating healthy aging benefits is no easy feat. [We] truly
appreciated [CERP’s] solid research project based on large-scale
cooperation between the body of researchers and institutions. [We]
were also impressed by the expertise, diversity, and dedication of
the product testing group.” (Source: NutraIngredients Awards
Brochure).
“Our team has worked diligently to set a standard for excellence
in industry-academic relationships and collaborations to support
the scientific advancement of Niagen® and NAD+,” said Dr. Yasmeen
Nkrumah-Elie, Global Director of Research & Development for
External Research at ChromaDex. “CERP differentiates ChromaDex from
other companies because the science is expansive and is primarily
investigator driven, and third-party funded. This award honors our
mission and we dedicate it to the investigators in our
program.”
Just this April 2022, CERP celebrated over 250 material transfer
agreements (MTAs) with over 235 independent scientists,
researchers, doctors, and investigators across 182 institutions and
33 countries. In Europe, CERP has established 70 material transfer
agreements with 58 institutions supporting research on
Ataxia-telangiectasia, skeletal muscle, heart health, among
others.
For additional information on ChromaDex’s 2022 NutraIngredients
Award, please click www.nutraingreients-awards.com and for more on
the science supporting Niagen visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to the value of CERP.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. Risks that contribute to the uncertain nature of these
forward-looking statements include the impact of the COVID-19
pandemic on our business and the global economy; our history of
operating losses and need to obtain additional financing; the
growth and profitability of our product sales; our ability to
maintain sales, marketing and distribution capabilities; changing
consumer perceptions of our products; our reliance on a single or
limited number of third-party suppliers; and the risks and
uncertainties associated with our business and financial condition.
More detailed information about ChromaDex and the risk factors that
may affect the realization of forward-looking statements is set
forth in ChromaDex's Annual Report on Form 10-K for the fiscal year
ended December 31, 2021, ChromaDex's Quarterly Reports on Form 10-Q
and other filings submitted by ChromaDex to the SEC, copies of
which may be obtained from the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and actual results may differ materially from those suggested by
these forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220517005235/en/
ChromaDex Media Contact: Kendall Knysch, Director of
Media Relations 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2024 to May 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From May 2023 to May 2024